spacer
home > ebr > Spring 2008
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2008
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR
   
Text
PDF
bullet
BioFinance and Management
In Freedom to Operate, John Mackle and Clive Lawrence at Clarion Solicitors take us through the various stages of litigation management of intellectual property necessary for the biological and pharmaceutical industries, informing everyone respectively of their rights  
view
download pdf
The biotechnology industry is demanding more and more high-calibre talent, yet the number of well-qualified Twenty-First Century Recruits is diminishing. Pete Leddy of Invitrogen examines this conundrum and the impact it will undoubtedly have on business success for the next few years  
view
download pdf
bullet
BioBusiness Development
Fewer and fewer pharma-biotech deals are being clinched, whether it is due to geographic relocation or a trend in pharmaceutical restructuring plans, leading Xavier Pinardon, Rodolphe Renac and Carlos Meca at Alcimed to ask, Deal or No Deal?  
view
download pdf
The EU pharmaceutical market may have become increasingly streamlined in recent years, but debate remains over the speed at which it is changing, particularly as regards the post-approval process, claim Alain J Gilbert and Mark Larkin at Bionest Partners in Cornering the EU Market: the Need for Creative Strategies  
view
download pdf
Cultural Competency is key to the global success of any international biotechnology company, argue Robin Ng and Judy Yeh at Dynamic Consultants International. Adeptly understanding and communicating with diverse cultures can significantly influence the global perception of a corporation  
view
download pdf
Robin Bhattacherjee of CV Therapeutics Europe outlines the regulatory complications and the strategic advantages that await the increasing number of biopharmaceutical companies who aim to take A Peek into Europe  
view
download pdf
Collaborate to Innovate is the message Heather Fraser at the IBM Institute for Business Value aims to convey. Biopartnering, if executed efficiently, can reap generous rewards both in terms of business success and product innovation, transforming the way in which businesses conduct such deals  
view
download pdf
bullet
BioResearch and Innovation
The latest developments in highly technological software solutions could revolutionise biopharmaceutical research.Michael Willett of Bruker Corporation discusses the various methodologies and viable options available, in Mass Spectrometry for the Next Generation  
view
download pdf
Optimised Peptide APIs facilitate effective drug delivery, but there are disadvantages inherent in their use that should not be overlooked. Udo Haberl, Hans-Georg Frank and Marco Emgenbroich at AplaGen GmbH evaluate the pharmacokinetic and pharamacodynamic optimisation of peptide APIs  
view
download pdf
Nick Barnett of Ocean Optics considers the significance of Raman spectroscopy as a tool for measuring active pharmaceutical ingredients and excipients as well as wider chemical analysis, in Modular Solutions for Low Resolution Raman Spectroscopy  
view
download pdf
bullet
Discovery Technology
Monoclonal antibodies are the most rapidly-expanding aspect of the therapeutic market, yet remain extremely high in cost due to manufacturing expense. Richard Buick, Nicolas Camper and Chris Scott at Fusion Antibodies discuss the cell line development that aims to increase cell productivity in The Antibody Effect  
view
download pdf
Matthew Segall at the ADMET Division, BioFocus DPI puts forward the question affecting almost every biopharmaceutical company: Why is it Still Drug Discovery? He investigates why the research and development process for the pharmaceutical industry is both expensive and of long duration, resulting in many failed projects  
view
download pdf
bullet
BioDevelopment and Regulatory
When Oral Bioavailability Becomes a Problem, it is crucial that companies assess the need for reliable prediction of preclinical bioavailability as well as the other limiting factors affecting this issue, assert Florence Salmon, Miriam Verwei and Robert Havenaar of TNO  
view
download pdf
The methods available to determine drugs and metabolites through bioanalysis are many and varied. Emma Waite at Tepnel Research Products and Services assesses the challenges of validation in comparison to chromatographic assays, in Validating Immunoassays: Best Practice Principles  
view
download pdf
The US is upping its game in order to compete with the EU in bringing biosimilars to the patients who need them. Following a Similar Path, by Suzanne Sensabaugh at MDS Pharma Services, evaluates the FDA’s role in this regulatory drive  
view
download pdf
bullet
BioFormulation and Manufacturing
Certain natural products when used as drugs combine high specificity and low side effects. Attaching poly(ethylene glycol) chains further improves their efficacy by enhancing bioavailability and biodistribution, claims Thomas Bruckdorfer at IRIS Biotech, in Drug Delivery with PEGylation  
view
download pdf
Find Your Niche advises David Rhodes of the Health Protection Agency, he investigates the notable development of speciality biotechnology products, continuing despite demands from many shareholders for greater numbers of ‘blockbuster’ drugs  
view
download pdf
Bridging Vaccine Translational Research is crucial in order for manufacturing strategy to influence vaccine development as well as monoclonal antibodies. Crawford Brown and Roger Lias of Eden Biodesign Inc assess how policy can target the unique properties of vaccines  
view
download pdf
bullet
BioRegional
The Basque Country is an increasingly vibrant bioregion, with an expanding cluster of innovative life science companies. In , María Aguirre at BioBasque explores this new bioscience hub, and the opportunities it can offer  
download pdf
European biotechnology companies continue to be attracted to the Australian research industry, due to its rapid expansion and progress. Nicola Watkinson of the Australian Government surveys the development and industry growth in this region, in Australian Research Excellence  
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Navigating the new Clinical Trial Regulation with DIA

For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will have a dramatic impact. The aim of the change in regulation is to increase the efficiency of all trials in Europe, as well as promoting research while avoiding the duplication of clinical trials
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

Industry Events

3D Cell Culture 2018

21-22 February 2018, Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement